Int J Med Sci 2014; 11(7):680-684. doi:10.7150/ijms.8916 This issue
1. Grup de Recerca Cardiovascular, Hospital Universitari de Sant Joan, IISPV, Universitat Rovira i Virgili, Reus, Spain.
2. Hospital de la Sta. Creu i St. Pau, Barcelona, Spain.
3. Hospital Virgen de la Salud, Toledo, Spain.
4. Hospital Universitari Parc Taulí, Sabadell, Spain.
5. LA-SER Outcomes, Oviedo, Spain.
6. Medical Department, Bayer HealthCare, Barcelona, Spain.
7. Hospital Clínico, Santiago de Compostela, Spain.
New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking.We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.
Keywords: vitamin K antagonists, dabigatran, health-related quality of life, new oral anticoagulants, ribaroxaban.